2022 - Research.com Best Female Scientist Award
2009 - Distinguished Scientist Award, American Heart Association
Evangelia G. Kranias mainly investigates Internal medicine, Phospholamban, Endocrinology, Contractility and Phosphorylation. Evangelia G. Kranias studied Internal medicine and Cardiology that intersect with Cause of death and Function. Her Phospholamban research is under the purview of Endoplasmic reticulum.
Evangelia G. Kranias has included themes like Cardiac function curve, Calcium metabolism and Troponin I in her Endocrinology study. Her research in Contractility intersects with topics in Inflammation, Pressure overload, Diastole, Sarcolipin and In vivo. Evangelia G. Kranias has researched Phosphorylation in several fields, including Molecular biology and Apoptosis.
Her main research concerns Internal medicine, Phospholamban, Endocrinology, Endoplasmic reticulum and Contractility. As part of the same scientific family, Evangelia G. Kranias usually focuses on Internal medicine, concentrating on Cardiology and intersecting with Diastole. Her Phospholamban study incorporates themes from SERCA, Ca2+/calmodulin-dependent protein kinase and Cardiac muscle.
Her Endocrinology research is multidisciplinary, incorporating perspectives in Ryanodine receptor, Dilated cardiomyopathy and Calcium-binding protein. Her studies deal with areas such as Biophysics and ATPase, Calcium ATPase as well as Endoplasmic reticulum. Her studies in Contractility integrate themes in fields like Genetically modified mouse, Contraction and In vivo.
Internal medicine, Phospholamban, Endocrinology, Heart failure and Ryanodine receptor are her primary areas of study. Her Internal medicine research includes elements of Ca2+/calmodulin-dependent protein kinase and Cardiology. Evangelia G. Kranias is doing genetic studies as part of her Endoplasmic reticulum and Phosphorylation and Phospholamban investigations.
Evangelia G. Kranias is interested in Myocyte, which is a field of Endocrinology. Her biological study spans a wide range of topics, including Muscle hypertrophy and Inotrope. Evangelia G. Kranias interconnects Stimulation and Ventricular remodeling in the investigation of issues within Contractility.
Evangelia G. Kranias spends much of her time researching Internal medicine, Phospholamban, Contractility, Endocrinology and Heart failure. The study incorporates disciplines such as Function and Cardiology in addition to Internal medicine. Her Phospholamban study is concerned with the larger field of Endoplasmic reticulum.
Her Endoplasmic reticulum research incorporates themes from Protein phosphatase 1, Dephosphorylation, Downregulation and upregulation and Post-transcriptional regulation. Her work deals with themes such as Calcium-binding protein, Calcium and Phosphorylation, which intersect with Endocrinology. Evangelia G. Kranias has included themes like Ventricular pressure and Myocardial infarction in her Heart failure study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Phospholamban: a crucial regulator of cardiac contractility
David H. MacLennan;Evangelia G. Kranias.
Nature Reviews Molecular Cell Biology (2003)
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation.
Wusheng Luo;Ingrid L. Grupp;Judy Harrer;Sathivel Ponniah.
Circulation Research (1994)
Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban.
Joachim P. Schmitt;Mitsuhiro Kamisago;Mitsuhiro Kamisago;Michio Asahi;Guo Hua Li.
PKC-alpha regulates cardiac contractility and propensity toward heart failure.
Julian C Braz;Kimberly Gregory;Anand Pathak;Wen Zhao.
Nature Medicine (2004)
Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy.
Susumu Minamisawa;Masahiko Hoshijima;Guoxiang Chu;Christopher A Ward.
Modulation of Cardiac Contractility by the Phopholamban/SERCA2a Regulatome
Evangelia G. Kranias;Roger J. Hajjar.
Circulation Research (2012)
Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human
Kobra Haghighi;Fotis Kolokathis;Luke Pater;Roy A. Lynch.
Journal of Clinical Investigation (2003)
Fibroblast growth factor 2 control of vascular tone.
Ming Zhou;Roy L. Sutliff;Richard J. Paul;John N. Lorenz.
Nature Medicine (1998)
The effect of troponin I phosphorylation on the Ca2+-binding properties of the Ca2+-regulatory site of bovine cardiac troponin.
S P Robertson;J D Johnson;M J Holroyde;E G Kranias.
Journal of Biological Chemistry (1982)
Phospholamban: A Prominent Regulator of Myocardial Contractility
Kimberly L. Koss;Evangelia G. Kranias.
Circulation Research (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: